[HTML][HTML] Personalized adoptive immunotherapy for patients with EBV-associated tumors and complications: Evaluation of novel naturally processed and presented …
Oncotarget, 2018•ncbi.nlm.nih.gov
Morbidity and mortality of immunocompromised patients are increased by primary infection
with or reactivation of Epstein-Barr virus (EBV), possibly triggering EBV+ post-transplant
lymphoproliferative disease (PTLD). Adoptive transfer of EBV-specific cytotoxic T cells (EBV-
CTLs) promises a non-toxic immunotherapy to effectively prevent or treat these
complications.
with or reactivation of Epstein-Barr virus (EBV), possibly triggering EBV+ post-transplant
lymphoproliferative disease (PTLD). Adoptive transfer of EBV-specific cytotoxic T cells (EBV-
CTLs) promises a non-toxic immunotherapy to effectively prevent or treat these
complications.
Abstract
Morbidity and mortality of immunocompromised patients are increased by primary infection with or reactivation of Epstein-Barr virus (EBV), possibly triggering EBV+ post-transplant lymphoproliferative disease (PTLD). Adoptive transfer of EBV-specific cytotoxic T cells (EBV-CTLs) promises a non-toxic immunotherapy to effectively prevent or treat these complications.
ncbi.nlm.nih.gov